The Vetr community last Friday upgraded Teva Pharmaceuticals Ltd. (ADR) ADR TEVA from 4 stars (Buy) to 4.5 stars (Strong Buy). Crowd confidence was very bullish, with 82.6 percent of the Vetr community giving the stock a buy rating and 17.4 percent a Sell.
See how crowdsourced ratings could help you time the market
This upgrade came despite news that Teva failed to meet endpoints in a late-stage asthma study, though there was little price movement at market close. The Vetr crowd remained bullish with a target price of $23.94 compared to the current share price of $20.98, implying a 13.93 percent upside.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.